Bisphosphonates for osteoporosis
Relevant BNF section: 6.6.2
One in three women and at least one in 12 men in the UK have osteoporosis, a condition which can lead to fractures, deformity, pain and disability, at a cost to the NHS of around £1.5 billion each year.1,2 Bisphosphonates offer a therapeutic option for preventing and treating osteoporosis. Here, we assess and compare the three bisphosphonates (alendronate, etidronate and ▼risedronate*) licensed for such use in the UK. We do not consider the four bisphosphonates (clodronate, pamidronate, tiludronate and ▼zoledronate) that are licensed in the UK only for the treatment of Paget's disease of bone and/or hypercalcaemia of malignancy.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
(2008). Annual {blacktriangledown}zoledronic acid for osteoporosis. DTB
46: 93-96
[Abstract] [Full Text] -
Jones, D. G., Savage, R., Highton, J.
(2005). Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome. BMJ
330: 74-74
[Full Text] -
Saad, F.
(2003). Bisphosphonates in Prostate Cancer: Where Are We and Where Should We Go?. JNCI J Natl Cancer Inst
95: 1262-1263
[Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Malignant disease and immunosuppression
-
Nutrition
-
Musculoskeletal and joint disorders
-
Oncology
-
Neurology
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
